3rd Annual Ligase Targeting Drug Development Summit
Evvnt Promotion / evvnt
11.04.2023 - 13.04.2023 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 am to 5:00 pm
Temi della conferenza
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.
From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases.
Scientific organizer
Hanson Wade
Hanson Wade
Annotazioni
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.
Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson and more.
Informazioni ed Iscrizioni:
https://go.evvnt.com/1450513-2?pid=4832
Mr. Alex Domingo
Sanità Pubblica (Public Health), Servizi sanitari
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
